Vasoconstriction-inhibiting factor: an endogenous inhibitor of vascular calcification as a calcimimetic of calcium-sensing receptor
Cardiovascular Research · 2025
DOI: 10.1093/cvr/cvaf016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Research, 2025. Verfasst von Sofía de la Puente-Secades und 20 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Cardiovascular Research (IMCAR), University Hospital RWTH Aachen, Pauwelsstraße 30, Aachen 52074, Germany. Hauptthemen laut MEDLINE: Vascular Calcification, Muscle, Smooth, Vascular, Receptors, Calcium-Sensing, Myocytes, Smooth Muscle. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: German Research Foundation, European Union's Horizon, German Society of Internal Medicine.
Abstract (Originalsprache)
Aims
Patients with chronic kidney disease (CKD) show a high risk of cardiovascular diseases, predominantly caused by accelerated vascular calcification. Vascular calcification is a highly regulated process with no current treatment. The vasoconstriction-inhibiting factor (VIF) peptide was recently discovered with vasoregulatory properties, but no information regarding calcification has been described. Methods and results In the present work, the inhibitory calcification effect of the VIF peptide was analysed in vitro in vascular smooth muscle cells (VSMCs), ex vivo in rat aortic rings, as well as in vivo in rats treated with vitamin D and nicotine (VDN). The VIF peptide inhibits vascular calcification by acting as a calcimimetic for the calcium-sensing receptor, increasing carboxylated matrix Gla protein production and blocking the activation of calcification pathways. The VIF peptide decreased calcium influx, the production of reactive oxygen species, and the activation of multiple kinases in VSMCs. Furthermore, calcium deposition in the aortas of patients with CKD negatively correlates with the VIF peptide concentration. Moreover, we show the cleavage of the VIF peptide from chromogranin-A by ‘proprotein convertase subtilisin/kexin type 2’ and ‘carboxypeptidase E’ enzymes. In addition, ‘cathepsin K’ degrades the VIF peptide. The active site of the native 35 amino acid-sequence long VIF peptide was identified with seven amino acids, constituting a promising drug candidate with promise for clinical translation.
Conclusion
The elucidation of the underlying mechanism by which the VIF peptide inhibits vascular calcification, as well as the active sequence and the cleavage and degradation enzymes, forms the basis for developing preventive and therapeutic measures to counteract vascular calcification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Molecular Cardiovascular Research (IMCAR), University Hospital RWTH Aachen, Pauwelsstraße 30, Aachen 52074, Germany.
- Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), University of Maastricht, Maastricht, The Netherlands.
- Institut National de la Santé Et de la Recherche Médicale (INSERM), RD-Néphrologie and EA7288, Montpellier, France.
- Institute of Experimental Medicine and Systems Biology, Division of Nephrology, University Hospital RWTH Aachen, Aachen, Germany.
- Division of Nephrology and Clinical Immunology, University Hospital RWTH Aachen, Aachen, Germany.
- Interdisciplinary Centre for Clinical Research (IZKF), University Hospital RWTH Aachen, Aachen, Germany.
ORCID-Profile: Sofía de la Puente-Secades, Dustin Mikolajetz, Àngel Argilés, Turgay Saritas, Emiel P C van der Vorst, Heidi Noels, Martin Tepel, Michael Wolf, Leon Schurgers, Joachim Jankowski
Förderung
- German Research Foundation
- European Union's Horizon
- German Society of Internal Medicine
- European Union’s Horizon
Zitieren
APA
de la Puente-Secades, S., Mikolajetz, D., Gayrard, N., Hermann, J., Jankowski, V., Bhargava, S., Meyer, A., Argilés, À., Saritas, T., van der Vorst, E. P. C., Wu, Z., Noels, H., Tepel, M., Alghamdi, K., Ward, D., Zidek, W., Wolf, M., Floege, J., Schurgers, L., …, & Jankowski, J. (2025). Vasoconstriction-inhibiting factor: an endogenous inhibitor of vascular calcification as a calcimimetic of calcium-sensing receptor. Cardiovascular Research. https://doi.org/10.1093/cvr/cvaf016
Vancouver
de la Puente-Secades S, Mikolajetz D, Gayrard N, Hermann J, Jankowski V, Bhargava S, et al. Vasoconstriction-inhibiting factor: an endogenous inhibitor of vascular calcification as a calcimimetic of calcium-sensing receptor. Cardiovascular Research. 2025. doi:10.1093/cvr/cvaf016
BibTeX
@article{delaPuenteSecades2025,
author = {de la Puente-Secades, Sofía and Mikolajetz, Dustin and Gayrard, Nathalie and Hermann, Juliane and Jankowski, Vera and Bhargava, Shruti and Meyer, Amina and Argilés, Àngel and Saritas, Turgay and van der Vorst, Emiel P C and Wu, Zhuojun and Noels, Heidi and Tepel, Martin and Alghamdi, Khaleda and Ward, Donald and Zidek, Walter and Wolf, Michael and Floege, Jürgen and Schurgers, Leon and Orth-Alampour, Setareh and Jankowski, Joachim},
title = {Vasoconstriction-inhibiting factor: an endogenous inhibitor of vascular calcification as a calcimimetic of calcium-sensing receptor},
journal = {Cardiovascular Research},
year = {2025},
doi = {10.1093/cvr/cvaf016}
}
EUVIMED